DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.

Author(s): Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S

Affiliation(s): aDepartment of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt/M, Germany bDepartment of Medicine, Division of Gastroenterology and Hepatology, Charite Medical Centre, Virchow Hospital, Medical School of the Humboldt University, Berlin, Germany cInternal Medicine II, Saarland University Hospital, Homburg/Saar, Germany dI. Medical Clinic, Clinic for General Internal Medicine, Christian-Albrechts University, Kiel, Germany eI. Department of Internal Medicine/Gastroenterology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany fDepartment of Internal Medicine I, University of Bonn, Bonn, Germany gDepartment of Gastroenterology and Hepatology, University of Cologne, Cologne, Germany hDepartment of Internal Medicine II, University Hospital Grosshadern, Ludwig-Maximilians University, Munich, Germany iDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Publication date & source: 2007-08, Eur J Gastroenterol Hepatol., 19(8):639-646.

AIM: The aim of this study was to investigate whether amantadine reduces deterioration of quality of life in patients with chronic hepatitis C during and after treatment with interferon-alpha (IFN-alpha) and ribavirin. PATIENTS AND METHODS: In this randomized, prospective, placebo-controlled, multicenter trial, previously untreated patients with chronic hepatitis C were treated with IFN-alpha plus ribavirin [] and randomized for treatment with amantadine (200 mg/day, orally, n=136) or placebo (n=131). Quality of life was assessed with the 'Profile of Mood States' scale and the 'Everyday Life' questionnaire at baseline, treatment week (TW) 8, TW24, TW48, and at follow-up. RESULTS: Early during treatment at TW8, quality of life was not different between patients in the control and the amantadine group. At TW24, the control group but not the amantadine group, however, showed significant deterioration of the modalities depression, fatigue, and vigor compared with baseline. Especially, nonresponders in the amantadine group showed significantly lower deterioration of depression, anger, mind function, everyday life, and zest for life than those in the placebo group. After treatment, the beneficial effects of amantadine disappeared. CONCLUSION: The addition of amantadine to IFN-alpha plus ribavirin combination therapy may reduce deterioration of depression, fatigue, and vigor during treatment but does not affect quality of life after treatment.

Page last updated: 2007-08-04

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017